Heinz Niels, Ehrnström Birgitta, Schambach Axel, Schwarzer Adrian, Modlich Ute, Schiedlmeier Bernhard
Research Group for Gene Modification in Stem Cells, LOEWE Center for Cell and Gene Therapy Frankfurt, Paul-Ehrlich-Institut, Langen, Germany; Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany.
Research Group for Gene Modification in Stem Cells, LOEWE Center for Cell and Gene Therapy Frankfurt, Paul-Ehrlich-Institut, Langen, Germany; Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany
Stem Cells Transl Med. 2015 Sep;4(9):1064-72. doi: 10.5966/sctm.2014-0284. Epub 2015 Jul 9.
Human cord blood (CB)-derived hematopoietic stem cells (HSCs) are an interesting source for HSC transplantation. However, the number of collected CB-HSCs is often too low for one transplantation; therefore, ex vivo expansion of CB-HSCs is desirable. Current expansion protocols are based on the use of cytokine combinations, including insulin-like growth factor-binding protein 2 (IGFBP2) and angiopoietin-like proteins, or combinations with "small molecules" such as stemregenin-1. The aim of our project was to compare the potential of different CB-HSC expansion strategies side-by-side by phenotypical analysis in vitro and serial engraftment properties in NOD/SCID/IL2rg-/- (NSG) immunodeficient mice. We further identified resveratrol, a naturally occurring polyphenol, as a new, alternative small molecule combined with cytokines to facilitate serum-free ex vivo expansion of human CB-HSCs. The cultivation in resveratrol preserved the CB-HSC phenotype in vitro most efficiently and was ∼2 times more potent than commonly used cytokine conditions (including stem cell factor, thrombopoietin, Fms-related tyrosine kinase 3 ligand, interleukin-6) and the recently established serum-free culture, including IGFBP2 and angiopoietin-like 5. Serial transplantation studies further confirmed resveratrol to support robust multilineage engraftment in primary and secondary NSG recipients. Therefore, our work proposes resveratrol as a new small molecule for improved ex vivo culture and modification of human HSCs based on an efficient ex vivo propagation of the HSC fate.
Human cord blood (CB)-derived hematopoietic stem cells (HSCs) are an important source for HSC transplantations but restricted in their usage because of their low numbers. In gene therapy, modifications of HSCs relies on their ex vivo modification without losing their stemness properties. Therefore, ex vivo cultivation and expansion of CB-HSCs is important for their effective application in HSC transplantation and gene therapy. Several promising protocols for serum-free cultivation of HSCs using different combinations of cytokines or so-called small molecules are described. A direct comparison was performed of three described serum-free cytokine conditions, demonstrating that the natural occurring polyphenol resveratrol is able to support ex vivo cultivation of CB-HSCs. The results show that resveratrol is an additional candidate for improving ex vivo cultures of HSCs for transplantation and gene therapeutic applications in the future.
人脐带血(CB)来源的造血干细胞(HSC)是HSC移植的一个有吸引力的来源。然而,采集的CB-HSC数量通常过低,无法进行一次移植;因此,CB-HSC的体外扩增是可取的。当前的扩增方案基于使用细胞因子组合,包括胰岛素样生长因子结合蛋白2(IGFBP2)和血管生成素样蛋白,或与“小分子”如干细胞再生因子-1的组合。我们项目的目的是通过体外表型分析和在NOD/SCID/IL2rg-/-(NSG)免疫缺陷小鼠中的连续植入特性,并排比较不同CB-HSC扩增策略的潜力。我们进一步鉴定了白藜芦醇,一种天然存在的多酚,作为一种新的替代小分子,与细胞因子联合使用,以促进人CB-HSC的无血清体外扩增。在白藜芦醇中培养最有效地在体外保留了CB-HSC表型,其效力比常用的细胞因子条件(包括干细胞因子、血小板生成素、Fms相关酪氨酸激酶3配体、白细胞介素-6)和最近建立的无血清培养(包括IGFBP2和血管生成素样蛋白5)高约2倍。连续移植研究进一步证实白藜芦醇可支持在原发性和继发性NSG受体中进行强大的多谱系植入。因此,我们的工作提出白藜芦醇作为一种新的小分子,用于基于HSC命运的高效体外增殖来改善人HSC的体外培养和修饰。
人脐带血(CB)来源的造血干细胞(HSC)是HSC移植的重要来源,但由于数量较少,其使用受到限制。在基因治疗中,HSC的修饰依赖于其体外修饰而不丧失其干性特性。因此,CB-HSC的体外培养和扩增对于其在HSC移植和基因治疗中的有效应用很重要。描述了几种使用不同细胞因子组合或所谓小分子进行HSC无血清培养的有前景的方案。对三种描述的无血清细胞因子条件进行了直接比较,表明天然存在的多酚白藜芦醇能够支持CB-HSC的体外培养。结果表明,白藜芦醇是未来改善用于移植和基因治疗应用的HSC体外培养的另一个候选物。